Gland Pharma Limited

Symbol: GLAND.NS

NSE

1688.1

INR

Market price today

  • 42.3302

    P/E Ratio

  • -1.6054

    PEG Ratio

  • 278.05B

    MRK Cap

  • 0.00%

    DIV Yield

Gland Pharma Limited (GLAND-NS) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.61%

Operating Profit Margin

0.19%

Net Profit Margin

0.13%

Return on Assets

0.00%

Return on Equity

0.08%

Return on Capital Employed

0.00%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Srinivas Sadu
Full-time employees:4585
City:Hyderabad
Address:Plot No. 11 & 84, TSIIC Phase: IV
IPO:2020-11-20
CIK:

Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.

General Outlook

When we look at how much money they make before expenses, they keep 0.605% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.189%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.134%. This tells us they're good at keeping money after all costs.

Return on Investments

Gland Pharma Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.081%.

Stock Prices

Gland Pharma Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1868.3, while its low point bottomed out at $1803.9. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Gland Pharma Limited's stock market.

Profitability Ratios

GLAND.NS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 19.25% underscores its earnings before tax deductions. The effective tax rate stands at 30.33%, revealing its tax efficiency. The net income per EBT, 69.67%, and the EBT per EBIT, 102.06%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 18.86%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin19.25%
Effective Tax Rate30.33%
Net Income per EBT69.67%
EBT per EBIT102.06%
EBIT per Revenue18.86%

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 35.15, and free cash flow per share, 35.15, depict cash generation on a per-share basis. The cash per share value, 130.22, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.12, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share35.15
Free Cash Flow per Share35.15
Cash per Share130.22
Operating Cash Flow Sales Ratio0.12
Free Cash Flow to Operating Cash Flow Ratio1.00

Debt and Leverage Ratios

An interest coverage of 50.22 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Interest Coverage50.22

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 28.06%, indicates top-line expansion, while the gross profit growth, 17.76%, reveals profitability trends. EBIT growth, 20.93%, and operating income growth, 20.93%, offer insights into operational profitability progression.

cards.indicatorcards.value
Revenue Growth28.06%
Gross Profit Growth17.76%
EBIT Growth20.93%
Operating Income Growth20.93%
EPS Growth17.03%
EPS Diluted Growth16.91%
Weighted Average Shares Growth3.84%
Weighted Average Shares Diluted Growth3.95%
Operating Cash Flow Growth30.72%
Free Cash Flow Growth-28.58%
10-Year Revenue Growth per Share179.77%
5-Year Revenue Growth per Share176.00%
3-Year Revenue Growth per Share118.79%
10-Year Operating CF Growth per Share56.66%
5-Year Operating CF Growth per Share289.18%
3-Year Operating CF Growth per Share324.59%
10-Year Net Income Growth per Share176.45%
5-Year Net Income Growth per Share275.40%
3-Year Net Income Growth per Share166.73%
10-Year Shareholders Equity Growth per Share329.40%
5-Year Shareholders Equity Growth per Share195.38%
3-Year Shareholders Equity Growth per Share148.77%
Receivables Growth-1.67%
Inventory Growth-7.02%
Asset Growth20.59%
Book Value per Share Growth16.76%
Debt Growth-5.05%
R&D Expense Growth32.48%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.36, and the price to book ratio, 3.36, reflect the market's valuation relative to the company's book value. The price to sales ratio, 5.68, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 48.16, and price to operating cash flows, 48.16, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.36
Price to Book Ratio3.36
Price to Sales Ratio5.68
Price Cash Flow Ratio48.16
Price Earnings to Growth Ratio-1.61
Enterprise Value Multiple20.54
Price Fair Value3.36
Price to Operating Cash Flow Ratio48.16
Price to Free Cash Flows Ratio48.16
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Gland Pharma Limited (GLAND.NS) on the NSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 42.330 in 2024.

What is the ticker symbol of Gland Pharma Limited stock?

The ticker symbol of Gland Pharma Limited stock is GLAND.NS.

What is company IPO date?

IPO date of Gland Pharma Limited is 2020-11-20.

What is company current share price?

Current share price is 1688.100 INR.

What is stock market cap today?

The market cap of stock today is 278048639100.000.

What is PEG ratio in 2024?

The current -1.605 is -1.605 in 2024.

What is the number of employees in 2024?

In 2024 the company has 4585.